Table 2.
Summary of findings.
| Comparison | Abstinence | Reduction | Cigarette consumption | SAE | |||
|---|---|---|---|---|---|---|---|
| End of intervention | Follow-up | End of intervention | Follow-up | End of intervention | Follow-up | Follow-up | |
| E-cigarette vs. placebo | RR: 1.97 [1.32, 2.93] I2: 33% |
RR: 1.66 [1.01, 2.73] I2: 0% |
RR: 1.22 [0.78, 1.92] I2: NA |
RR: 1.31 [1.02, 1.68] I2: 0% |
MD: 2.97[1.38, 4.57] I2: 89% |
MD: 1.39 [0.30, 2.48] I2: 0% |
RR: 1.22 [0.54, 2.78] I2: 0% |
| E-cigarette vs. NRT | RR: 1.37[1.18–1.59] I2: 53% |
RR: 1.49 [1.14, 1.95] I2: 70% |
RR: 1.48 [1.04, 2.10] I2: 51% |
RR: 1.47 [1.18, 1.82] I2: 0% |
MD: 1.69 [1.63-1.76] I2: 95% | MD: 0.81 [0.00 – 1.61] I2: 84% |
RR: 1.53 [1.02, 2.30] I2:13% |
SAE, Serious adverse effects; RR, Risk ratio; NRT, Nicotine replacement therapy; MD, Mean difference/Risk Ratio (M-H, Fixed, 95% CI)/Mean Difference (IV, Fixed, 95% CI)/Bold: p ≤ 0.05/.